BioNTech CEO Ugur Sahin sells 49K shares

BioNTech’s CEO Ugur Sahin sold 49,000 ordinary shares under a Rule 10b5-1 plan while retaining over 39 million shares indirectly through Medine GmbH.

Rhea-AI Filing Summary

BioNTech SE (BNTX) Chief Executive Officer and ten percent owner Ugur Sahin reported open-market sales of BioNTech ordinary shares under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. He sold 15,000 ordinary shares on September 16, 2026 at an average price of $96.0893 per share and 34,000 ordinary shares on September 15, 2026 at an average price of $96.4893 per share, for total reported sales of 49,000 shares.

Following these transactions, a reported 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder. The filing notes that 106,721 of these shares are held in trust, where Medine GmbH has voting but not dispositive power, and that Sahin may be deemed to beneficially own the shares held by Medine GmbH.

Insider Trade Summary 10b5-1

Net Seller: 49,000 shares

Net Sell 3 txns

Insider Sahin Ugur

Role Chief Executive Officer

Sold 49,000 shs ($4.72M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	15,000	$96.0893	$1.44M
Sale	Ordinary Shares	34,000	$96.4893	$3.28M
holding	Ordinary Shares F1	--	--	--

Holdings After Transaction: Ordinary Shares — 553,209 shares (Direct); Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)

Footnotes (1)

1. F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Key Figures

Shares sold on September 16, 2026: 15,000 shares Average sale price on September 16, 2026: $96.0893 per share Shares sold on September 15, 2026: 34,000 shares +5 more

8 metrics

Shares sold on September 16, 2026 15,000 shares Open-market sale of BioNTech ordinary shares by Ugur Sahin

Average sale price on September 16, 2026 $96.0893 per share Sale of 15,000 ordinary shares

Shares sold on September 15, 2026 34,000 shares Open-market sale of BioNTech ordinary shares by Ugur Sahin

Average sale price on September 15, 2026 $96.4893 per share Sale of 34,000 ordinary shares

Total shares sold 49,000 shares Combined open-market sales reported in this Form 4

Indirect holdings through Medine GmbH 39,218,111 shares Ordinary shares held indirectly as of September 15, 2026

Shares held in trust 106,721 shares Ordinary shares where Medine GmbH has voting but not dispositive power

Rule 10b5-1 plan adoption date June 3, 2026 Trading plan under which the reported sales were effected

Key Terms

Rule 10b5-1 trading plan, beneficially own, dispositive power, Ordinary Shares

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

beneficially own financial

"The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

dispositive power financial

"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Ordinary Shares financial

"The ordinary shares are held by Medine GmbH"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BNTX CEO Ugur Sahin report in this Form 4?

He reported two open-market sales of BioNTech ordinary shares: 34,000 shares on September 15, 2026 at $96.4893 per share and 15,000 shares on September 16, 2026 at $96.0893 per share, totaling 49,000 shares sold.

Were the BNTX share sales by Ugur Sahin made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan established by Ugur Sahin on June 3, 2026, indicating the trades were pre-arranged under that plan.

What is Ugur Sahin’s reported indirect ownership in BNTX after these transactions?

The filing reports 39,218,111 BioNTech ordinary shares held indirectly through Medine GmbH. Ugur Sahin is the sole shareholder of Medine GmbH and may be deemed to beneficially own the shares it holds.

How many BNTX shares in Sahin’s indirect holdings are held in trust?

The filing notes that 106,721 ordinary shares are held for the benefit of an individual under a trust arrangement, where Medine GmbH exercises voting power but not dispositive power over those shares while they are held in trust.

Does Ugur Sahin have direct or indirect ownership for the reported BNTX holdings?

The reported post-transaction holdings of 39,218,111 ordinary shares are classified as indirect ownership through Medine GmbH. The sales of 49,000 shares were from directly owned ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:46 PM Accepted by SEC EDGAR 09/16/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sahin Ugur

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/15/2026		S		34,000	D	$96.4893	568,209	D
Ordinary Shares	09/16/2026		S		15,000	D	$96.0893	553,209	D
Ordinary Shares								39,218,111	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Remarks:

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.

	/s/ Humza Bokhari, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)